TY - JOUR T1 - Pro: should asymptomatic patients with moderate-to-severe OSA be treated? JF - Breathe JO - Breathe SP - 7 LP - 10 DO - 10.1183/20734735.0340-2018 VL - 15 IS - 1 AU - Silke Ryan Y1 - 2019/03/01 UR - http://breathe.ersjournals.com/content/15/1/7.abstract N2 - Obstructive sleep apnoea (OSA) is a highly prevalent condition representing a major global public health burden [1]. Attributed to the prominent symptom of excessive daytime sleepiness, it leads to significant impairments in quality of life, cognitive performance and social functioning and to a dramatic increase in road traffic and occupational accidents [2]. However, the major health burden in OSA patients is due to the significant association with cardiovascular and metabolic diseases, such as systemic arterial hypertension, coronary artery disease, heart failure, stroke or type 2 diabetes leading to substantial morbidity and mortality [3, 4]. Continuous positive airway pressure (CPAP) therapy which acts to splint the upper airway open during sleep is the treatment of choice, particularly for patients with moderate or severe disease. CPAP often has a dramatic effect on a patient's awake performance. It improves objective and subjective sleepiness, quality of life, neurocognitive function and driving performance [5].Substantial evidence points to a benefit with CPAP on cardiovascular and metabolic outcomes in asymptomatic patients with moderate-to-severe obstructive sleep apnoea http://ow.ly/FUxN30nkTqU ER -